Table 1.
siRNA/Inhibitor Treatment | Inhibit Proliferation | Average Fold Knockdown | Regeneration Pathway/Category |
---|---|---|---|
CEBPG | Yes | −3.92 | AP-1 Pathway |
JNK inhibitor | Yes | ||
JUND | Yes | * | |
| |||
BTAF1 | Yes | −1.57 | AP-1 siRNA Commonalities |
LRP5 | Yes | −5.71 | |
RARA | Yes | −1.41 | |
| |||
PAX2 | Yes | −1.61 | Pax Pathway |
PAX3 | No | −1.61 | |
PAX5 | Yes | * | |
PAX7 | No | −1.72 | |
| |||
MYT1L | No | * | AP-1/Pax siRNA Commonalities |
WNT4 | Yes | −2.27 | |
| |||
CUTL1 | Yes | −1.86 | Cell Cycle |
p27KIP | No | −2.93 | |
ID1 | No | −1.48 | |
| |||
CBX3 | No | −4.15 | Polycomb Complex |
CBX4 | No | −1.09 | |
EZH2 | No | −1.87 | |
| |||
IGF inhibitor | No | Pathway Inhibitors | |
MAPK inhibitor | Yes | ||
SHH inhibitor | No | ||
| |||
HRY | No | −1.30 | Notch Signaling |
| |||
BCL11A | No | −1.35 | Common to all tissues/damage |
TRIP15 | No | −1.12 | |
| |||
CTNNB1 | No | −2.39 | Common to cochlea and utricle |
| |||
TIME | No | −1.16 | Early regeneration |
| |||
PPARGC1 | No | −1.42 | Neomycin specific |
Proliferation phenotypes were quantified for each siRNA knockdown. Inhibition was determined as a significantly lower proliferation index as compared to a GFP siRNA control (p value < 0.05). Knockdowns of siRNA targets were confirmed by microarray analysis or (*) end-point semi-quantitative PCR.